Ambrx

Ambrx is at the forefront of innovation in precision biologics, specializing in next-generation antibody-drug conjugates (ADCs) and employing expanded genetic code technology. This approach allows for the incorporation of synthetic amino acids into proteins, resulting in product candidates designed for highly stable site-specific conjugation, addressing the challenges of conventional methods.

Recently, Ambrx has made significant strides in its oncology portfolio, focusing on enhanced ADCs, immuno-oncology conjugates, and bispecific candidates as potential treatments for cancer. The company was acquired by Johnson & Johnson in March 2024, following shareholder approval, marking a new chapter in its commitment to advancing cancer therapies.

Generated from the website